Acorda Therapeutics upgraded by HC Wainwright & Co. with a new price target

6/17/21 6:09:07 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACOR

Date	Price Target	Rating	Analyst